Steady progress in clinical trials and global layout
Continuously delve deeper

IDOV-Safe™, the core product of Longyao Biotech, is currently undergoing clinical trials at the four top-tier oncology centers in China. It has achieved a historic breakthrough in the treatment of microsatellite-stable (MSS) colorectal cancer, and demonstrated significant therapeutic potential in the treatment of recalcitrant cancers such as triple-negative breast cancer, non-small cell lung cancer and gastric cardia cancer. IDOV-Immune™, the company’s upgraded strategic product, has completed IND (Investigational New Drug) filing with the U.S. Food and Drug Administration (FDA) and initiated Phase I clinical trials in Sydney. Its proprietary mechanism design and preclinical data across multiple cancer types are both superior to those of the previous-generation product, marking a crucial expansion of the company’s therapeutic boundaries in the field of oncolytic virus therapy...